Table 2. Outcomes During Surveillance.
| Outcome | No./No. (%) |
|---|---|
| Surveillance time, median (IQR), mo | 51.5 (28-84) |
| Progression to either WF or HRS | 130/540 (24.1) |
| Progression to WF as first event | 127/540 (23.5) |
| Size >30 mm | 57/127 (44.9) |
| Increase of size >5 mm within 24 mo | 101/127 (79.5) |
| MPD diameter 5-9 mm | 24/127 (18.9) |
| Enhancing nodule <5 mm | 4/127 (3.1) |
| Acute pancreatitis | 3/127 (2.3) |
| Progression to HRS as first event | 3/540 (0.6) |
| Pancreatic surgery | 15/540 (2.8) |
| High-grade dysplasia or cancer on pathologic testing | 7/540 (1.3) |
| Death from any cause | 31/540 (5.7) |
| Pancreas-related death | 3/540 (0.6) |
Abbreviations: HRS, high-risk stigmata; IQR, interquartile range; MPD, main pancreatic duct; WF, worrisome feature.